What Is Retatrutide?

Retatrutide (research code LY3437943) is an experimental peptide developed by Eli Lilly and Company. It belongs to a group of compounds known as incretin-based agonists, which copy the action of hormones released by the gut after a meal. What sets retatrutide apart is that one molecule activates three receptors: those for GIP, GLP-1 and glucagon. For this reason it is often called a triple agonist or, informally, "triple G".

The Three Hormones Behind the Name

Each of the three target receptors normally responds to a natural hormone with its own job in the body:

• GLP-1 is released from the intestine after eating. It prompts the pancreas to release insulin when blood sugar is high, slows the emptying of the stomach and acts on appetite centres in the brain.
• GIP is another gut hormone that boosts insulin release after meals. Research suggests it also affects fat tissue and may influence how well GLP-1-type drugs are tolerated.
• Glucagon is made by the pancreas and usually raises blood sugar between meals. It also increases energy use and fat breakdown in the liver, which is why researchers are interested in adding it to weight-focused compounds.

In the original laboratory work published by Lilly scientists in Cell Metabolism (2022), retatrutide was more potent at the GIP receptor than at the human GLP-1 and glucagon receptors, where its activity was roughly balanced. In obese mice, the glucagon component added a rise in energy expenditure on top of the reduced food intake driven by the GIP and GLP-1 components.

How the Molecule Is Built

Retatrutide is a chain of 39 amino acids. Its backbone is based on the GIP hormone sequence, with several changes that make it resistant to rapid breakdown in the blood:

• Two positions carry 2-aminoisobutyric acid (Aib), an unusual amino acid. The one near the start of the chain protects it from the enzyme DPP-4.
• One leucine carries an extra methyl group (α-methyl-leucine), another stabilising change.
• A lysine side chain is linked, through a short spacer and a glutamic acid unit, to a 20-carbon fatty diacid. This fatty tail lets the peptide bind reversibly to albumin in the blood, which slows its clearance.
• The chain ends in an amide group (serinamide) rather than a free acid.

Why It Lasts About a Week

Natural GLP-1 is broken down within minutes. Because of its albumin-binding fatty tail and its protective amino acids, retatrutide stayed in circulation far longer in clinical studies. A 12-week Phase 1b trial in people with type 2 diabetes, published in The Lancet in 2022, measured a half-life of roughly six days, which is why every clinical trial has tested it as a once-weekly injection under the skin.

How It Differs from Semaglutide and Tirzepatide

Semaglutide acts on the GLP-1 receptor alone. Tirzepatide, also made by Lilly, acts on the GIP and GLP-1 receptors. Retatrutide adds glucagon receptor activity. The idea is that GIP and GLP-1 mainly reduce how much is eaten, while glucagon adds higher energy use and more fat burning in the liver. No head-to-head trial comparing retatrutide with tirzepatide or semaglutide has been published yet, so claims that it is "stronger" than these drugs rest on comparisons between separate studies, which can be misleading.

Key Points to Remember

• Retatrutide is one engineered peptide, not a mixture of three hormones.
• Its receptor profile favours GIP, with roughly balanced GLP-1 and glucagon activity.
• Human data come from controlled clinical trials; there is no approved product.
• Long-term effects beyond about 80 weeks of treatment have not been published.